Skip to main content
. 2015 Nov 27;7(1):845–859. doi: 10.18632/oncotarget.6417

Figure 7. MEKI and ABT-263 synergize to reduce tumor growth in vivo.

Figure 7

A. HL60 cells were subcutaneously injected in NSG mice and mice were treated five days a week with vehicle control, MEKI (0.2 mg/kg), ABT-263 (1 mg/kg) or both. The growth rate was calculated from the measurement of the tumour volume twice a week and defined as the increase in mm3/day in each mouse. The graph represents the values of two independent experiments performed on 10 mice/group for each experiment. B. Histological sections of tumours stained with anti-activated caspase 3 antibody. A significant field of slides in tumours from either vehicle-, MEKI-, ABT-263- or MEKI + ABT-263-fed mice is shown as indicated.